Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:CMRX NASDAQ:CRNX NASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$40.39+1.9%$32.56$16.50▼$43.58$3.52BN/A11,795 shs7,108 shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.91 million shsN/ACRNXCrinetics Pharmaceuticals$31.11-5.8%$31.00$24.10▼$62.53$2.91B0.25820,245 shs923,475 shsIMVTImmunovant$17.91-2.0%$15.86$12.72▼$34.47$3.06B0.631.22 million shs1.03 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+1.94%+5.62%+12.57%+115.76%+4,038,999,900.00%CMRXChimerix0.00%0.00%0.00%0.00%+805.62%CRNXCrinetics Pharmaceuticals-5.78%-2.57%+2.00%+2.27%-42.23%IMVTImmunovant-2.02%-1.21%+12.93%+18.22%-40.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/ACMRXChimerix0.6308 of 5 stars1.00.00.04.10.01.70.6CRNXCrinetics Pharmaceuticals3.3537 of 5 stars3.40.00.03.71.82.50.0IMVTImmunovant1.5357 of 5 stars3.40.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/ACMRXChimerix 2.00Hold$8.53-0.08% DownsideCRNXCrinetics Pharmaceuticals 2.80Moderate Buy$69.50123.40% UpsideIMVTImmunovant 2.82Moderate Buy$36.30102.68% UpsideCurrent Analyst Ratings BreakdownLatest CMRX, IMVT, AAPG, and CRNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025CRNXCrinetics PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$36.007/10/2025IMVTImmunovantThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$18.006/27/2025CRNXCrinetics PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.004/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$134.35M26.19N/AN/A$0.48 per share84.15CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94CRNXCrinetics Pharmaceuticals$1.04M2,800.80N/AN/A$14.29 per share2.18IMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$55.54MN/A0.00∞N/AN/AN/AN/AN/ACMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)CRNXCrinetics Pharmaceuticals-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)IMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)Latest CMRX, IMVT, AAPG, and CRNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CRNXCrinetics Pharmaceuticals-$1.13N/AN/AN/A$0.52 millionN/A8/5/2025Q1 2026IMVTImmunovant-$0.69N/AN/AN/AN/AN/A5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/8/2025Q1 2025CRNXCrinetics Pharmaceuticals-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/ACRNXCrinetics PharmaceuticalsN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International3.241.261.26CMRXChimerixN/A6.336.33CRNXCrinetics PharmaceuticalsN/A22.5322.53IMVTImmunovantN/A11.1611.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/ACMRXChimerix45.42%CRNXCrinetics Pharmaceuticals98.51%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/ACMRXChimerix13.10%CRNXCrinetics Pharmaceuticals4.60%IMVTImmunovant1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.12 millionN/AN/ACMRXChimerix9093.80 million78.15 millionOptionableCRNXCrinetics Pharmaceuticals21093.63 million89.32 millionOptionableIMVTImmunovant120171.07 million167.99 millionOptionableCMRX, IMVT, AAPG, and CRNX HeadlinesRecent News About These CompaniesAll You Need to Know About Immunovant (IMVT) Rating Upgrade to BuyJuly 16 at 1:01 PM | zacks.comWall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?July 16 at 10:56 AM | zacks.comEmerald Advisers LLC Trims Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)July 14, 2025 | marketbeat.comImmunovant (IMVT) chief technology officer Stout sells $26k in stockJuly 13, 2025 | investing.comPrincipal Financial Group Inc. Sells 31,255 Shares of Immunovant, Inc. (NASDAQ:IMVT)July 13, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $19,998.40 in StockJuly 12, 2025 | insidertrades.comImmunovant (NASDAQ:IMVT) Rating Increased to Hold at The Goldman Sachs GroupJuly 12, 2025 | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Insider Michael Geffner Sells 1,160 SharesJuly 11, 2025 | marketbeat.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CTO Sells 1,519 Shares of StockJuly 11, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Coverage Initiated by Analysts at The Goldman Sachs GroupJuly 10, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 7, 2025 | marketbeat.comLifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PTJuly 6, 2025 | msn.comImmunovant, Inc. (IMVT) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comImmunovant (NASDAQ:IMVT) Stock Updated Nasdaq CompositeJune 23, 2025 | kalkinemedia.comKZacks Research Comments on Immunovant FY2028 EarningsJune 23, 2025 | marketbeat.comTracking Baker Brothers Portfolio - Q1 2025 UpdateJune 17, 2025 | seekingalpha.comImmunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)June 13, 2025 | seekingalpha.comImmunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?June 2, 2025 | zacks.comIMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in FocusMay 30, 2025 | zacks.comImmunovant, Inc. Reports Strategic Progress and Financial ResultsMay 29, 2025 | tipranks.comImmunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The FenceMay 29, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMRX, IMVT, AAPG, and CRNX Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$40.39 +0.77 (+1.94%) As of 07/18/2025 04:00 PM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Chimerix NASDAQ:CMRXChimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Crinetics Pharmaceuticals NASDAQ:CRNX$31.11 -1.91 (-5.78%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$31.46 +0.34 (+1.11%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Immunovant NASDAQ:IMVT$17.91 -0.37 (-2.02%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$18.03 +0.12 (+0.67%) As of 07/18/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
